I
Ikaria
Develop and deliver innovative therapeutics and interventions to meet the significant needs of critically
About Ikaria
Ikaria Inc. operated as a fully-integrated biotherapeutics company with a dedicated focus on the critical care market. The company was incorporated in Delaware in August 2006, initially as ITL Holdings, Inc., before changing its name to Ikaria Holdings, Inc. in 2007 and finally to Ikaria, Inc. in 2010. The modern iteration of the company was shaped by the 2007 merger between the legacy Ikaria, Inc. and INO Therapeutics LLC. David Shaw was the founding CEO, later serving as executive chair.
The firm’s business centered on developing and commercializing innovative therapies and interventions for critically ill patients, primarily within the hospital setting. Its flagship product was the INOMAX® therapy package, an all-inclusive offering that combined the INOMAX® (nitric oxide) drug for inhalation with a proprietary drug-delivery system, comprehensive on-site training for clinicians, and continuous 24/7 technical support. This integrated model positioned Ikaria as a key partner to hospitals, particularly in neonatal intensive care units (NICUs).
The primary application for INOMAX is as the only FDA-approved treatment for term and near-term newborn babies experiencing hypoxic respiratory failure connected with pulmonary hypertension. The therapy functions as a vasodilator to improve oxygenation and critically reduces the need for extracorporeal membrane oxygenation (ECMO), a complex and invasive life-support procedure. The company's revenue was driven by the sale of this bundled drug, device, and service package. A significant milestone in the company's history occurred in April 2015, when it was acquired by Mallinckrodt plc for approximately $2.3 billion. This acquisition was a strategic move for Mallinckrodt to bolster its hospital portfolio and expand its footprint into the specialized field of neonatal critical care.
Source: Dealroom company dataNews
Open roles
Ikaria in the Hampton ecosystem
The Ikaria office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Venrock
Aravis Ventures
ARCH Venture Partners
5AM Ventures
Series B and later2 investors entered at this stage
New Mountain Capital
Black Point Group
Source: Dealroom Talent Intelligence.
Patents
43 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Ikaria on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

